DOCSLIB.ORG

595 PART 441—PENEM ANTIBIOTIC DRUGS Subpart A—Bulk Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
595 PART 441—PENEM ANTIBIOTIC DRUGS Subpart A—Bulk Drugs Food and Drug Administration, HHS § 441.20a (6) pH. Proceed as directed in § 436.202 imipenem per milliliter at 25 °C is ¶85° of this chapter, using an aqueous solu- to ¶95° on an anhydrous basis. tion containing 60 milligrams per mil- (vi) It gives a positive identity test. liliter. (vii) It is crystalline. (7) Penicillin G content. Proceed as di- (2) Labeling. It shall be labeled in ac- rected in § 436.316 of this chapter. cordance with the requirements of (8) Crystallinity. Proceed as directed § 432.5 of this chapter. in § 436.203(a) of this chapter. (3) Requests for certification; samples. (9) Heat stability. Proceed as directed In addition to complying with the re- in § 436.214 of this chapter. quirements of § 431.1 of this chapter, [42 FR 59873, Nov. 22, 1977; 43 FR 2393, Jan. 17, each such request shall contain: 1978, as amended at 45 FR 22922, Apr. 4, 1980; (i) Results of tests and assays on the 50 FR 19918, 19919, May 13, 1985] batch for potency, sterility, pyrogens, loss on drying, specific rotation, iden- PART 441ÐPENEM ANTIBIOTIC tity, and crystallinity. DRUGS (ii) Samples, if required by the Direc- tor, Center for Drug Evaluation and Subpart AÐBulk Drugs Research: (a) For all tests except sterility: 10 Sec. 441.20a Sterile imipenem monohydrate. packages, each containing approxi- mately 500 milligrams. Subpart BÐ[Reserved] (b) For sterility testing: 20 packages, each containing equal portions of ap- Subpart CÐInjectable Dosage Forms proximately 300 milligrams. 441.220 Imipenem monohydrate-cilastatin (b) Tests and methods of assayÐ(1) Po- sodium injectable dosage forms. tency. Proceed as directed in § 436.216 of 441.220a Sterile imipenem monohydrate- this chapter, using a column heater cilastatin sodium. which will maintain a 50 °C column 441.220b Imipenem monohydrate-cilastatin temperature, and ultraviolet detection sodium for injection. system operating at a wavelength of AUTHORITY: Sec. 507 of the Federal Food, 254 nanometers, a column packed with Drug, and Cosmetic Act (21 U.S.C. 357). microparticulate (3 to 10 micrometers in diameter) reversed phase packing Subpart AÐBulk Drugs material such as octyl or octadecyl hy- drocarbon bonded silicas, a flow rate of § 441.20a Sterile imipenem 2.0 milliliters per minute, and a known monohydrate. injection volume of 10 microliters. Re- (a) Requirements for certificationÐ(1) agents, working standard and sample Standards of identity, strength, quality, solutions, system suitability require- and purity. Imipenem monohydrate is ments, and calculations are as follows: the monohydrate form of [5R-[5α, 6α, (i) ReagentsÐ(a) Phosphate buffer, (R*)]]-6-(1-hydroxyethyl)-3-[[2- 0.001M. Dissolve 272 milligrams of [(iminomethyl) amino]ethyl]thio]-7- monobasic potassium phosphate in oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-car- 1,800 milliliters of deionized water. Ad- boxylic acid. It is a white to tan col- just the pH to 6.8 with 0.5N sodium hy- ored powder. It is so purified and dried droxide or dilute phosphoric acid. Di- that: lute to 2,000 milliliters with deionized (i) Its potency is not less than 900 water and filter prior to use. micrograms and not more than 1,050 (b) Mobile phase. Dissolve 2.0 grams of micrograms of imipenem per milligram 1-hexanesulfonic acid, sodium salt in on an anhydrous basis. 800 milliliters of phosphate buffer, (ii) It is sterile. 0.001M. Adjust the pH to 6.8 with 0.5N (iii) It is nonpyrogenic. sodium hydroxide or dilute phosphoric (iv) Its loss on drying is not less than acid and dilute to 1,000 milliliters with 5.0 percent and not more than 8.0 per- phosphate buffer, 0.001M. Filter and cent. degas the mobile phase just prior to its (v) Its specific rotation in an aqueous introduction into the chromatograph solution containing 5 milligrams of pumping system. 595 VerDate 17<JUL>96 11:55 Jul 29, 1996 Jkt 167069 PO 00000 Frm 00590 Fmt 8010 Sfmt 8010 C:\CFR\21V5.001 pfrm13 § 441.20a 21 CFR Ch. I (4±1±96 Edition) (c) 0.1 Percent bicarbonate solution. Alternate chromatographic conditions Dissolve 50 milligrams of sodium bicar- are acceptable provided reproducibility bonate in 40 milliliters of phosphate and resolution are comparable to the buffer, 0.001M, and dilute to 50 milli- system. However, the sample prepara- liters with phosphate buffer, 0.001M. tion described in paragraph (b)(1)(ii)(b) (d) 0.9 Percent saline solution. Dissolve of this section should not be changed. 9.0 grams of sodium chloride in 800 mil- (iv) Calculations. Calculate the liliters of deionized water and dilute to micrograms of imipenem per milligram 1.0 liter with deionized water. of sample as follows: (ii) Preparations of working standard and sample solutionsÐ(a) Working stand- ard solution. Accurately weigh approxi- Micrograms of AP× ×100 imipenem per = u s mately 25 milligrams of the imipenem × × − working standard into a 50-milliliter milligram ACLs u ()100 volumetric flask. Immediately prior to where: analysis, add 10 milliliters of 0.9 per- Au=Area of the imipenem peak in the chro- cent saline solution and 1 milliliter of matogram of the sample (at a retention 0.1 percent bicarbonate solution. Add time equal to that observed for the phosphate buffer, 0.001M, and shake standard); until dissolved. Sonicate, if necessary, As=Area of the imipenem peak in the chro- but for no longer than 1 minute. Dilute matogram of the imipenem working to volume with phosphate buffer, standard; 0.001M, to obtain a solution containing Ps=Anhydrous imipenem activity in the approximately 500 micrograms of imipenem working standard solution in micrograms per milliliter; imipenem per milliliter. Mix well and Cu=Milligrams of sample per milliliter of inject immediately. sample solution; and (b) Sample solution. Dissolve an accu- L=Percent loss on drying of the sample. rately weighed portion (approximately 25 milligrams) of the sample with 10 (2) Sterility. Proceed as directed in milliliters of 0.9 percent saline solution § 436.20 of this chapter, using the meth- and 1 milliliter of 0.1 percent bicarbon- od described in paragraph (e)(1) of that ate solution in a 50-milliliter volu- section. metric flask. Dilute the sample solu- (3) Pyrogens. Proceed as directed in tion to volume with phosphate buffer, § 436.32(a) of this chapter, using a solu- 0.001M, to obtain a solution containing tion containing 5.0 milligrams of 500 micrograms of imipenem per milli- imipenem per milliliter, except inject liter (estimated). 10 milliliters per kilogram of rabbit (iii) System suitability requirementsÐ weight. (a) Tailing factor. The tailing factor (4) Loss on drying. Proceed as directed (T) is satisfactory if it is not more than in § 436.200(i) of this chapter. 1.5 at 10 percent of peak height in lieu of 5 percent of peak height. (5) Specific rotation. Dilute an accu- (b) Efficiency of the column. The effi- rately weighed sample with sufficient ciency of the column (n) is satisfactory pH 7.0 phosphate buffer to give a con- if it is greater than 600 theoretical centration of approximately 5.0 milli- plates for a 30-centimeter column. grams of imipenem per milliliter. Pro- (c) Resolution. The resolution (R) be- ceed as directed in § 436.210 of this chap- tween the peaks for thienamycin and ter, using a 1.0-decimeter polarimeter imipenem is satisfactory if it is not tube. To prepare the pH 7.0 phosphate less than 2.0. buffer, transfer 5 grams of monobasic (d) Coefficient of variation (relative potassium phosphate and 11 grams of standard deviation). The coefficient of dibasic potassium phosphate to a 1.0- variation (SRinpercent) of 5 replicate liter volumetric flask. Dissolve and di- injections is satisfactory if it is not lute to volume with distilled water. more than 2.0 percent. (6) Identity. Proceed as directed in If the system suitability requirements § 436.211 of this chapter, using the sam- have been met, then proceed as de- ple preparation described in paragraph scribed in § 436.216(b) of this chapter. (b)(2) of that section. 596 VerDate 17<JUL>96 11:55 Jul 29, 1996 Jkt 167069 PO 00000 Frm 00591 Fmt 8010 Sfmt 8010 C:\CFR\21V5.001 pfrm13 Food and Drug Administration, HHS § 441.220a (7) Crystallinity. Proceed as directed (ii) Samples, if required by the Direc- in § 436.203(a) of this chapter. tor, Center for Drug Evaluation and [51 FR 11573, Apr. 4, 1986; 51 FR 16517, May 5, Research: 1986, as amended at 55 FR 11582, Mar. 29, 1990; (A) The imipenem monohydrate used 59 FR 8133, Feb. 18, 1994] in making the batch: 10 packages, each containing approximately 500 milli- Subpart BÐ[Reserved] grams. (B) The batch: Subpart CÐInjectable Dosage (1) For all tests except sterility: A Forms minimum of 20 immediate containers. (2) For sterility testing: 20 immediate § 441.220 Imipenem monohydrate- containers, collected at regular inter- cilastatin sodium injectable dosage vals throughout each filling operation. forms. (b) Tests and methods of assayÐ(1) § 441.220a Sterile imipenem Imipenem and cilastatin potency and con- monohydrate-cilastatin sodium. tent. Determine the potency of the sample in micrograms per milligram of (a) Requirements for certificationÐ(1) both imipenem and cilastatin and the Standards of identity, strength, quality, milligrams of both imipenem and and purity. Imipenem monohydrate- cilastatin per container. Proceed as di- cilastatin sodium is a dry mixture of rected in § 441.20a(b)(1), preparing the imipenem monohydrate and cilastatin cilastatin reference standard solution, sodium packaged for dispensing. Its po- the sample solution and calculating tency is satisfactory if it contains not the imipenem and cilastatin potency less than 400 micrograms of imipenem and content as follows: and not less than 400 micrograms of cilastatin per milligram.
Load more

Recommended publications
  • 28912 Oxoid FDA Cartridge Tables:1
    * Adapted in part from CLSI document M100-S23 (M02-A11) : “Disc diffusion supplemental tablesʼʼ Performance standards for antimicrobial susceptibility testing. The complete standard may be obtained from the Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19807. Test Cultures (zone diameters in mm) Antimicrobial Agent Disc Code Potency Resistant Intermediate Susceptible Amikacin AK 30 μg EnterobacteriaceaeK, P. aeruginosa, Acinetobacter spp., and Staphylococcus spp. ≤14 15-16 ≥17 Amoxycillin - Clavulanic Acid AMC 20/10 μg EnterobacteriaceaeE ≤13 14-17 ≥18 Staphylococcus spp.A,Q ≤19 — ≥20 Haemophilus spp.A,Y ≤19 — ≥20 AmpicillinC,n AMP 10 μg EnterobacteriaceaeE and Vibrio choleraef ≤13 14-16 ≥17 Staphylococcus spp.A,Q ≤28 — ≥29 Enterococcus spp.A,V,W,k,m ≤16 — ≥17 Haemophilus spp.Y ≤18 19-21 ≥22 Streptococcus spp. ß-Hemolytic GroupA,d — — ≥24 Ampicillin – Sulbactam SAM 10/10 μg EnterobacteriaceaeE, Acinetobacter spp., and Staphylococcus spp. ≤11 12-14 ≥15 Haemophilus spp.A,Y ≤19 — ≥20 Azithromycin AZM 15 μg Staphylococcus spp., Streptococcus spp Viridans Groupn, ß-Hemolytic Group, and S. pneumoniae) ≤13 14-17 ≥18 Neisseria meningitidisA,i — — ≥20 Haemophilus spp.A — — ≥12 Aztreonam ATM 30 μg EnterobacteriaceaeE ≤17 18-20 ≤21 P. aeruginosa ≤15 16-21 ≥22 Haemophilus spp.A — — ≥26 CAR 100 μg Carbenicillin Enterobacteriaceae ≤19 20-22 ≥23 Pseudomonas aeruginosaP ≤13 14-16 ≥17 CEC 30 μg Cefaclor Enterobacteriaceae and Staphylococcus spp. ≤14 15-17 ≥18 Haemophilus spp.Y ≤16 17-19 ≥20 MA 30 μg Cefamandole EnterobacteriaceaeD,E and Staphylococcus spp. ≤14 15-17 ≥18 CefazolinG KZ 30 μg Staphylococcus spp.
    [Show full text]
  • Virtual Screening of Inhibitors Against Envelope Glycoprotein of Chikungunya Virus: a Drug Repositioning Approach
    www.bioinformation.net Research Article Volume 15(6) Virtual screening of inhibitors against Envelope glycoprotein of Chikungunya Virus: a drug repositioning approach Garima Agarwal1, Sanjay Gupta1, Reema Gabrani1, Amita Gupta2, Vijay Kumar Chaudhary2, Vandana Gupta3* 1Center for Emerging Diseases, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, UP 201309, India: 2Centre for Innovation in Infectious Disease Research, Education and Training, University of Delhi South Campus, Benito Juarez Marg, New Delhi 110021, India: 3Department of Microbiology, Ram Lal Anand College, University of Delhi South Campus (UDSC), Benito Juarez Marg, New Delhi 110021, India. Vandana Gupta – E-mail: [email protected]; Phone: +91 7838004880 Received April 1, 2019; Accepted April 16, 2019; Published June 15, 2019 DOI: 10.6026/97320630015439 Abstract: Chikungunya virus (CHIKV) a re-emerging mosquito-borne alpha virus causes significant distress which is further accentuated in the lack of specific therapeutics or a preventive vaccine, mandating accelerated research for anti-CHIKV therapeutics. In recent years, drug repositioning has gained recognition for the curative interventions for its cost and time efficacy. CHIKV envelope proteins are considered to be the promising targets for drug discovery because of their essential role in viral attachment and entry in the host cells. In the current study, we propose structure-based virtual screening of drug molecule on the crystal structure of mature Chikungunya envelope protein (PDB 3N41) using a library of FDA approved drug molecules. Several cephalosporin drugs docked successfully within two binding sites prepared at E1-E2 interface of CHIKV envelop protein complex with significantly low binding energies. Cefmenoxime, ceforanide, cefotetan, cefonicid sodium and cefpiramide were identified as top leads with a cumulative score of -67.67, -64.90, -63.78, -61.99, and - 61.77, forming electrostatic, hydrogen and hydrophobic bonds within both the binding sites.
    [Show full text]
  • Download Download
    VOLUME 7 NOMOR 2 DESEMBER 2020 ISSN 2548 – 611X JURNAL BIOTEKNOLOGI & BIOSAINS INDONESIA Homepage Jurnal: http://ejurnal.bppt.go.id/index.php/JBBI IN SILICO STUDY OF CEPHALOSPORIN DERIVATIVES TO INHIBIT THE ACTIONS OF Pseudomonas aeruginosa Studi In Silico Senyawa Turunan Sefalosporin dalam Menghambat Aktivitas Bakteri Pseudomonas aeruginosa Saly Amaliacahya Aprilian*, Firdayani, Susi Kusumaningrum Pusat Teknologi Farmasi dan Medika, BPPT, Gedung LAPTIAB 610-612 Kawasan Puspiptek, Setu, Tangerang Selatan, Banten 15314 *Email: [email protected] ABSTRAK Infeksi yang diakibatkan oleh bakteri gram-negatif, seperti Pseudomonas aeruginosa telah menyebar luas di seluruh dunia. Hal ini menjadi ancaman terhadap kesehatan masyarakat karena merupakan bakteri yang multi-drug resistance dan sulit diobati. Oleh karena itu, pentingnya pengembangan agen antimikroba untuk mengobati infeksi semakin meningkat dan salah satu yang saat ini banyak dikembangkan adalah senyawa turunan sefalosporin. Penelitian ini melakukan studi mengenai interaksi tiga dimensi (3D) antara antibiotik dari senyawa turunan Sefalosporin dengan penicillin-binding proteins (PBPs) pada P. aeruginosa. Tujuan dari penelitian ini adalah untuk mengklarifikasi bahwa agen antimikroba yang berasal dari senyawa turunan sefalosporin efektif untuk menghambat aktivitas bakteri P. aeruginosa. Struktur PBPs didapatkan dari Protein Data Bank (PDB ID: 5DF9). Sketsa struktur turunan sefalosporin digambar menggunakan Marvins Sketch. Kemudian, studi mengenai interaksi antara antibiotik dan PBPs dilakukan menggunakan program Mollegro Virtual Docker 6.0. Hasil yang didapatkan yaitu nilai rerank score terendah dari kelima generasi sefalosporin, di antaranya sefalotin (-116.306), sefotetan (-133.605), sefoperazon (-160.805), sefpirom (- 144.045), dan seftarolin fosamil (-146.398). Keywords: antibiotik, penicillin-binding proteins, P. aeruginosa, sefalosporin, studi interaksi ABSTRACT Infections caused by gram-negative bacteria, such as Pseudomonas aeruginosa, have been spreading worldwide.
    [Show full text]
  • 12. What's Really New in Antibiotic Therapy Print
    What’s really new in antibiotic therapy? Martin J. Hug Freiburg University Medical Center EAHP Academy Seminars 20-21 September 2019 Newsweek, May 24-31 2019 Disclosures There are no conflicts of interest to declare EAHP Academy Seminars 20-21 September 2019 Antiinfectives and Resistance EAHP Academy Seminars 20-21 September 2019 Resistance of Klebsiella pneumoniae to Pip.-Taz. olates) EAHP Academy Seminars 20-21 September 2019 https://resistancemap.cddep.org/AntibioticResistance.php Multiresistant Pseudomonas Aeruginosa Combined resistance against at least three different types of antibiotics, 2017 EAHP Academy Seminars 20-21 September 2019 https://atlas.ecdc.europa.eu/public/index.aspx Distribution of ESBL producing Enterobacteriaceae EAHP Academy Seminars 20-21 September 2019 Rossolini GM. Global threat of Gram-negative antimicrobial resistance. 27th ECCMID, Vienna, 2017, IS07 Priority Pathogens Defined by the World Health Organisation Critical Priority High Priority Medium Priority Acinetobacter baumanii Enterococcus faecium Streptococcus pneumoniae carbapenem-resistant vancomycin-resistant penicillin-non-susceptible Pseudomonas aeruginosa Helicobacter pylori Haemophilus influenzae carbapenem-resistant clarithromycin-resistant ampicillin-resistant Enterobacteriaceae Salmonella species Shigella species carbapenem-resistant fluoroquinolone-resistant fluoroquinolone-resistant Staphylococcus aureus vancomycin or methicillin -resistant Campylobacter species fluoroquinolone-resistant Neisseria gonorrhoae 3rd gen. cephalosporin-resistant
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Use of Long Half-Life Parenteral Cephalosporins in Ambulatory Practice
    Use of Long Half-Life Parenteral Cephalosporins in Ambulatory Practice Mark Sauerwein, MD, Robert L. Deamer, PharmD, and John G. Prichard, MD Ventura, California, and Houston, Texas Cefonicid (Monocid) and ceftriaxone (Rocephin) are long half-life cephalos­ porins that may be used for serious infections in the outpatient setting. They may be used as an extension of initial hospital treatment, or therapy can be initiated and completed in many cases with the patient remaining at home. Sufficient clinical experience exists with both ceftriaxone and cefonicid to recommend these agents for selected patients having pyelonephritis, os­ teomyelitis, or soft tissue infections. Cefonicid, perhaps in combination with erythromycin, will provide excellent coverage for complicated community- acquired pneumonias. Ceftriaxone is effective as single-dose therapy for even complicated gonococcal infections. The use of long half-life cephalo­ sporins in ambulatory practice may result in substantial cost savings for certain patients. linicians are at times frustrated by prolonged management of selected infections are herein re­ C hospitalizations of those who are not acutely ill viewed. simply to provide parenteral antibiotic therapy. Pa­ Cefonicid (Monocid, Smith Kline & French) is a tients and their families may be equally disconcerted broad-spectrum cephalosporin that because of its because of the high cost and disruption consequent to spectrum of activity is typically grouped as a second- hospitalization. Nevertheless, the physician may wish generation agent. Cefonicid is usually administered in­ to initiate parenteral antibiotic therapy for a particular travenously or intramuscularly in doses of 1 to 2 g, and illness, such as pyelonephritis or pneumonia, as the because of its extended four-hour half-life, it can be clinical circumstances can create apprehension about given once every 24 hours (Table 1).
    [Show full text]
  • Effect of Storage Temperature and Ph on the Stability of Antimicrobial Agents in MIC Trays JONZ-MEI DEBRA HWANG, TONI E
    JOURNAL OF CLINICAL MICROBIOIOGY, May 1986. p. 959-961 Vol. 23, No. S 0095-1137/86/050959-03$02.00/0 Copyright © 1986. American Society for Microbiology Effect of Storage Temperature and pH on the Stability of Antimicrobial Agents in MIC Trays JONZ-MEI DEBRA HWANG, TONI E. PICCININI, CLAUDIA J. LAMMEL, W. KEITH HADLEY, AND GEO F. BROOKS* Departnent of Laboratorv Medicine, University of Califo)r-nia, Sani Friancisco, Califorzia 94143 Received 25 November 1985/Accepted 15 January 1986 Twelve antimicrobial agents, ampicillin, aztreonam, cefamandole, cefazolin, cefonicid, ceforanide, ceftazi- dime, ceftizoxime, ceftriaxone, cefuroxime, ciprofloxacin, and norfloxacin, were prepared at pH 6.80 and 7.31 in microdilution trays for storage at 4, -10, -25, and -70°C and for weekly susceptibility testing. All 12 drugs had stable biological activity when stored at -70°C for I year. All but ampicillin and aztreonam were stable at -25°C. Storage at -10°C was least satisfactory. Desiccation occurred at 40C, but short-term storage at this temperature is possible since the antimicrobial agents are stable for up to several months. The routine use of microdilution trays for antimicrobial aireius ATCC 29213, Escherichia (oli ATCC 25922. and susceptibility testing requires a knowledge of the stability of Pseuidomizonas aeruigin.osa ATCC 27853, were the same as in the antimicrobial agents when stored at different tempera- the previous study (1). These bacteria had at least one and tures. A previous report from our laboratory showed data for usually two endpoints within the range of drug concentra- 11 beta-lactams prepared at two pHs and stored at four tions selected.
    [Show full text]
  • Development of an Antibiotic Policy in a Zoological Medicine Service and Approach to Antibiotic Dosing Using Minimum Inhibitory Concentration Data Stephen J
    Development of an Antibiotic Policy in a Zoological Medicine Service and Approach to Antibiotic Dosing Using Minimum Inhibitory Concentration Data Stephen J. Divers, BVetMed, DZooMed, DipECZM (Herpetology), DipECZM (Zoo Health Management), Dipl ACZM, FRCVS, Izidora Sladakovic, BVSc (Hons I), MVS, Jörg Mayer, DVM, MS, DipECZM (Exotic Mammals), Dipl ACZM, DABVP (Exotic Companion Mammal Practice), Susan Sanchez, BSc, MSc, PhD, FRSB Session #2101 Affiliation: From The Department of Small Animal Medicine and Surgery (Divers, Sladakovic, Mayer) and Athens Veterinary Diagnostic Laboratory (Sanchez), College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA. Abstract: Antimicrobial resistance is a major veterinary concern, and yet despite widespread literature and policies advocating appropriate antibiotic stewardship in domesticated veterinary medicine, there appears to have been very little progress in zoological medicine, especially companion exotic practice. An example of an antibiotic policy for a zoological medicine service is described, along with general advice on appropriate antibiotic use, including minimum inhibitory concentration (MIC)-determined drug dosing. Introduction Antimicrobial resistance (AMR) is a global veterinary and public health challenge, which has accelerated by the overuse of antibiotics worldwide. Increased antimicrobial resistance is the cause of severe infections, complica- tions, longer hospital stays and increased mortality. Overprescribing of antibiotics is associated with an increased risk
    [Show full text]
  • Antimicrobial Stewardship Antimicrobial Stewardship: Systems and Processes for Effective Antimicrobial Medicine Use
    NICE Medicines and prescribing centre DRAFT for consultation Antimicrobial stewardship Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use Medicines practice guideline Appendices August 2015 National Institute for Health and Care Excellence Disclaimer This guideline represents the views of NICE and was arrived at after careful consideration of the evidence available. Those working in the NHS, local authorities, the wider public, voluntary and community sectors and the private sector should take it into account when carrying out their professional, managerial or voluntary duties. Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Copyright National Institute for Health and Care Excellence 2015 Declarations of interest Contents Appendices .......................................................................................................................... 5 Appendix A: Declarations of interest ............................................................................ 5 A.1 Guideline development group (GDG) members .............................................. 5 A.2
    [Show full text]
  • Antibiotic Resistance: Bioinformatics-Based Understanding As a Functional Strategy for Drug Cite This: RSC Adv., 2020, 10, 18451 Design
    RSC Advances View Article Online REVIEW View Journal | View Issue Antibiotic resistance: bioinformatics-based understanding as a functional strategy for drug Cite this: RSC Adv., 2020, 10, 18451 design Umar Ndagi, *a Abubakar A. Falaki,b Maryam Abdullahi,c Monsurat M. Lawald and Mahmoud E. Soliman e The use of antibiotics to manage infectious diseases dates back to ancient civilization, but the lack of a clear distinction between the therapeutic and toxic dose has been a major challenge. This precipitates the notion that antibiotic resistance was from time immemorial, principally because of a lack of adequate knowledge of therapeutic doses and continuous exposure of these bacteria to suboptimal plasma concentration of antibiotics. With the discovery of penicillin by Alexander Fleming in 1924, a milestone in bacterial infections' treatment was achieved. This forms the foundation for the modern era of antibiotic drugs. Antibiotics such as penicillins, cephalosporins, quinolones, tetracycline, macrolides, sulphonamides, Creative Commons Attribution-NonCommercial 3.0 Unported Licence. aminoglycosides and glycopeptides are the mainstay in managing severe bacterial infections, but resistant strains of bacteria have emerged and hampered the progress of research in this field. Recently, new approaches to research involving bacteria resistance to antibiotics have appeared; these involve combining the molecular understanding of bacteria systems with the knowledge of bioinformatics. Consequently, many molecules have been developed to curb resistance associated with different bacterial infections. However, because of increased emphasis on the clinical relevance of antibiotics, the Received 15th February 2020 synergy between in silico study and in vivo study is well cemented and this facilitates the discovery of Accepted 1st May 2020 potent antibiotics.
    [Show full text]
  • E3 Appendix 1 (Part 1 of 2): Search Strategy Used in MEDLINE
    This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at [email protected] Appendix 1 (part 1 of 2): Search strategy used in MEDLINE # Searches 1 exp *anti-bacterial agents/ or (antimicrobial* or antibacterial* or antibiotic* or antiinfective* or anti-microbial* or anti-bacterial* or anti-biotic* or anti- infective* or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or clindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).kf,kw,ti. or (antimicrobial or antibacterial or antiinfective or anti-microbial or anti-bacterial or anti-infective or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or c lindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).ab. /freq=2 2 alamethicin/ or amdinocillin/ or amdinocillin pivoxil/ or amikacin/ or amoxicillin/ or amphotericin b/ or ampicillin/ or anisomycin/ or antimycin a/ or aurodox/ or azithromycin/ or azlocillin/ or aztreonam/ or bacitracin/ or bacteriocins/ or bambermycins/ or bongkrekic acid/ or brefeldin a/ or butirosin sulfate/ or calcimycin/ or candicidin/ or capreomycin/ or carbenicillin/ or carfecillin/ or cefaclor/ or cefadroxil/ or cefamandole/ or cefatrizine/ or cefazolin/ or cefixime/ or cefmenoxime/ or cefmetazole/ or cefonicid/ or cefoperazone/
    [Show full text]